Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration (US FDA)-approved therapy for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stern, Robert M., Connell, Nathan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737867/
https://www.ncbi.nlm.nih.gov/pubmed/31534662
http://dx.doi.org/10.1177/2040620719874728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737867/
https://www.ncbi.nlm.nih.gov/pubmed/31534662
http://dx.doi.org/10.1177/2040620719874728

Ejemplares similares